Compare EPAM Systems Inc (EPAM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Novo Nordisk A/S — how do they compare? EPAM Systems Inc trades at $86.92 (market cap $4.49B), while Novo Nordisk A/S trades at $50.65 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 49.5× EPAM Systems Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | NVO | |
|---|---|---|
Market Cap | $4.49B | $222.24B |
Sector | Technology | Health |
52-Week High | $221.40 | $71.70 |
52-Week Low | $76.04 | $35.29 |
Enterprise Value | $3.74B | $241.20B |
Dividend Yield | — | 3.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
